Latest Earnings Results: Q2 '26
Estimated EPS
$2.94
Reported EPS
$3.60
Surprise
+22.49%
Estimated Rev
$2.46B
Reported Rev
$2.74B
Surprise
+11.2%
• Reported GAAP EPS of $0.66 down -84.76% YoY • Reported revenue of $2.74B up 3.42% YoY • Biogen expects full year 2026 Non-GAAP diluted EPS of $12.00 to $13.00, while total revenue is projected to increase by a mid-single digit percentage compared to 2025 for Biogen.
Bullish Takeaway
Biogen delivered strong 24% growth in its expanding Growth Portfolio, highlighted by significant demand increases for SKYCLARYS and EMPAVELI, alongside successful product launches and regulatory approvals for new therapeutic options.
Bearish Takeaway
Biogen experienced a 13% decline in Multiple Sclerosis revenue and significantly lower GAAP diluted EPS, while facing structural risks from product concentration and the inherent uncertainty of drug development pipelines.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | $2.20 | -- | -- | N/A |
Q2 '26 | $2.94 | $3.60 | 22.49% | BEAT |
Q1 '26 | $3.08 | $3.57 | 15.77% | BEAT |
Q4 '25 | $1.63 | $1.99 | 22.45% | BEAT |
Q3 '25 | $3.88 | $4.81 | 23.89% | BEAT |